CCR5 and atherosclerosis: Based on the evidences that CCL5/CCR5 pathway involves in progression of atherosclerosis or intimal hyperplasia, several studies reported that maraviroc, an antagonist of CCR5, showed decreasing atherosclerosis or intimal hyperplasia [31,32].